Inventor · disambiguated record
Xianglin Shi
Also filed as: SHI XIANGLIN
7 granted patents·6 pending applications·31 citations·filing 2011–2024
82Inventor score
Files withBIOGEN MA INC6BIOGEN IDEC INC2SUNESIS PHARMACEUTICALS INC2VIRACTA THERAPEUTICS INC2ZHANG PEILIN1
Top patents by PatentIndex Score
13 records- 0191US9944622B2Pyrimidinyl tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Apr 17, 2018·8 cites·16 claims
- 0291US9353087B2Inhibitors of Bruton's tyrosine kinaseBIOGEN IDEC INC·Filed 2013·Granted May 31, 2016·8 cites·19 claims
- 0389US9394277B2Pyrimidinyl tyrosine kinase inhibitorsBIOGEN IDEC INC·Filed 2013·Granted Jul 19, 2016·11 cites·26 claims
- 0484US10618887B2Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·3 cites·17 claims
- 0583US2024417389A1Pyrimidinyl tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0677US2023174511A1Pyrimidinyl tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0768US2021017155A1Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0867US11142545B2Synthesis of thiolated oligonucleotides without a capping stepBIOGEN MA INC·Filed 2017·Granted Oct 12, 2021·1 cites·21 claims
- 0963US10189817B2Inhibitors of Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Jan 29, 2019·0 cites·6 claims
- 1054US2017114039A1Inhibitors of bruton's tyrosine kinaseBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 1150US2023406878A1Oligonucleotides, reagents, and preparation thereofBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 1248US12378276B2Convergent liquid phase syntheses of oligonucleotidesBIOGEN MA INC·Filed 2020·Granted Aug 5, 2025·0 cites·17 claims
- 1335US2013084587A1Levels of cytokeratins in blood and body fluids as biomarkers for cancer screening, diagnosis and treatment monitoringZHANG PEILIN·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →